The American Journal of Managed Care

ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management

Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson. Discuss the data presented at ASCO 2024 on the RELATIVITY-047 study of nivolumab plus relatlimab vs ...
ascopubs.org

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...
MedPage Today

Relatlimab and Nivolumab vs Nivolumab in Previously Untreated Metastatic/Unresectable Melanoma: Overall Survival and Response From RELATIVITY-047

RELATIVITY-047, a global, randomized, double-blind, phase II/III study, met its primary endpoint of progression-free survival (PFS). Relatlimab and nivolumab (RELA + NIVO) as a fixed-dose combination ...
Nasdaq

Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo (nivolumab ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 2/3 RELATIVITY-047 trial, which showed that the fixed-dose combination of relatlimab, a LAG-3 ...
Nasdaq

European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for ...

The Phase 2/3 RELATIVITY-047 trial served as the basis for this application, in which a statistically significant and clinically meaningful benefit was observed with relatlimab and nivolumab over ...